PositiveID's
FireflyDX Prototype Detects
Flu Types; Chief
Science Officer Explains Why
Accurate Flu Detection at Point of Care Enables Smart Treatment
Decisions in Interview
with SmallCapVoice.com
Austin, TX
-- January
31, 2018 --
InvestorsHub NewsWire -- SmallCapVoice.com, Inc. today
announced it conducted a new audio interview with
PositiveID
Corporation ("PositiveID" or the "Company") (OTC:
PSID), a life sciences
company focused on detection and diagnostics, regarding
the
Company's successful detection
of the influenza virus on its FireflyDX real-time polymerase chain
reaction (PCR) breadboard prototype system ("prototype
system"). The interview can
be heard at https://smallcapvoice.com/blog/1-30-18-smallcapvoice-interview-with-positiveid-corporation-psid.
In the
interview, Dr. Kimothy
Smith, Chief Science Officer
of PositiveID
and its
ExcitePCR Corporation subsidiary, announced
the
Company's successful detection of the influenza virus on
its
FireflyDX
prototype
system and
its
publication of
a white paper. Smith described the
limitations of current rapid influenza detection tests, and
discussed how FireflyDX could enable correct diagnosis at the point
of care for smart treatment decisions. PositiveID and
ExcitePCR are developing FireflyDX, in both portable and handheld
forms, to enable fast,
accurate
diagnosis at the point of care
or point of need (POC/PON).
The FireflyDX family
of products, currently under
development, is designed to
provide accurate, rapid pathogen detection using real-time PCR in
less than 30 minutes, with minimally trained personnel and at a
lower cost than existing systems. Current solutions for accurately
identifying potential pathogens and bio-threats, especially at the
POC/PON, can sometimes take as long as several hours to several
days to provide results, dramatically delaying what is often
life-saving treatment. Five different flu
virus assays (Type A; Type B; H3N3; H7N1; and, H5N1) were tested on
the FireflyDX prototype system in the
lab.
SmallCapVoice.com is a recognized
corporate investor relations firm, with clients nationwide, known
for its ability to help emerging growth companies build a following
among retail and institutional investors. SmallCapVoice.com
utilizes its stock newsletter to feature its daily stock picks,
audio interviews, as well as its clients' financial news releases.
SmallCapVoice.com also offers individual investors all the tools
they need to make informed decisions about the stocks they are
interested in. Tools like stock charts, stock alerts, and Company
Information Sheets can assist with investing in stocks that are
traded on the OTC BB and Pink Sheets. To learn more about
SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About PositiveID
Corporation
PositiveID
Corporation is a life sciences tools and diagnostics company with
an extensive patent portfolio. PositiveID develops biological
detection and diagnostics systems, specializing in the development
of microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID is also a leader in
the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect with
PositiveID on Twitter, Facebook or LinkedIn.
On August 24, 2017,
PositiveID Corporation and its wholly-owned subsidiary PositiveID
Diagnostics, Inc. (collectively, the "Seller"), entered into an
Asset Purchase Agreement ("APA") with ExcitePCR Corporation.
Pursuant to the APA, at closing, the Seller will sell and deliver
to ExcitePCR all assets used in connection with the operation of
the FireflyDX technology. For more information on the APA, please
read PositiveID's Form 8-K filed on August 28, 2017, which can be
found here.
Statements about PositiveID's
future expectations, including the likelihood that
FireflyDX could enable correct diagnosis at the point of care
for smart treatment decisions; the likelihood that
PositiveID and ExcitePCR are developing FireflyDX, in both
portable and handheld forms, to enable fast, accurate diagnosis at
the POC/PON; constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and
PositiveID's actual results could differ materially from expected
results. These risks and uncertainties include, without limitation,
the Company's ability to complete the
development, testing and
commercialization of the FireflyDX-Portable and
FireflyDX-Handheld; the Company's ability to target the
professional healthcare market; the Company's ability to raise
capital; the Company's and ExcitePCR's ability to
close the APA; as well as other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings
with the Securities and Exchange Commission, including those set
forth in the Company's 10-K filed on March 31, 2017, and 10-Qs
filed on November 13, 2017, August 14, 2017,
and May 15, 2017, under the caption "Risk Factors."
The Company undertakes no obligation to update or release any
revisions to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by
law.
Contact:
PositiveID
Corporation
Allison
Tomek
(561)
805-8044
atomek@psidcorp.com
Stuart Smith
SmallCapVoice.com